Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 8, 2026, 9:15 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1225–1248 of 6,600 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Multi Center Clear all

Conditions: Severe Preeclampsia
Interventions: AMAG-423 (digoxin immune fab), Placebo; Biological · Other
Lead sponsor: AMAG Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 58 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 16
States / cities: Mobile, Alabama • Kansas City, Kansas • Louisville, Kentucky + 12 more

Conditions: Distal Radius Fracture
Interventions: Open Reduction and Internal Fixation, External Fixation, Percutaneous Pinning, Closed Reduction and casting; Procedure
Lead sponsor: University of Michigan; Other
Eligibility: 60 Years and older
Enrollment: 304 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2019
U.S. locations: 20
States / cities: Farmington, Connecticut • Louisville, Kentucky • Baltimore, Maryland + 15 more

Conditions: Severe Hemophilia A
Interventions: rFVIIIFc; Drug
Lead sponsor: Bioverativ Therapeutics Inc.; Industry
Eligibility: 12 Years and older · Male only
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 5
States / cities: Los Angeles, California • Sacramento, California • Waltham, Massachusetts + 2 more

Conditions: Lung Transplant
Interventions: Cyclosporine Inhalation Solution (CIS); Drug
Lead sponsor: APT Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 15
States / cities: Los Angeles, California • San Francisco, California • Stanford, California + 12 more

Conditions: Hodgkin's Lymphoma
Interventions: Obatoclax mesylate (GX15-070MS); Drug
Lead sponsor: Gemin X; Industry
Eligibility: 18 Years and older
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Spinal Muscular Atrophy
Interventions: Nusinersen; Drug
Lead sponsor: Biogen; Industry
Eligibility: 0 Weeks to 6 Weeks
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2024
U.S. locations: 11
States / cities: Los Angeles, California • Sacramento, California • Aurora, Colorado + 8 more

Conditions: Schizophrenia
Interventions: CT-155 smartphone app; Device
Lead sponsor: Click Therapeutics, Inc.; Industry
Eligibility: 18 Years to 64 Years
Enrollment: 72 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022
U.S. locations: 10
States / cities: Culver City, California • Garden Grove, California • La Habra, California + 7 more

Conditions: Multiple Myeloma
Interventions: Vorinostat, Bortezomib, pegylated liposomal doxorubicin; Drug
Lead sponsor: UNC Lineberger Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2017
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Bacterial Vaginosis
Interventions: SYM-1219, Placebo; Drug
Lead sponsor: Symbiomix Therapeutics; Industry
Eligibility: 12 Years and older · Female only
Enrollment: 189 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015
U.S. locations: 21
States / cities: Birmingham, Alabama • Jonesboro, Arkansas • San Diego, California + 17 more

Conditions: Parkinson's Disease
Interventions: ABBV-0805, Placebo ABBV-0805; Drug
Lead sponsor: AbbVie; Industry
Eligibility: Up to 85 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020
U.S. locations: 5
States / cities: Gainesville, Florida • New York, New York • Durham, North Carolina + 2 more

Conditions: Metastatic Castration Resistant Prostate Cancer (mCRPC)
Interventions: AAA617, ARPI: Abiraterone, ARPI: Enzalutamide; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 100 Years · Male only
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 5
States / cities: Casa Grande, Arizona • Gilbert, Arizona • Newport Beach, California + 2 more

Conditions: Diabetes, Diabetes Mellitus, Type 2
Interventions: Insulin detemir, Insulin NPH, Diet/exercise; Drug · Behavioral
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 10 Years to 18 Years
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 23
States / cities: Tucson, Arizona • Los Angeles, California • Jacksonville, Florida + 19 more

Conditions: Neoplasms
Interventions: Refametinib (BAY86-9766), Regorafenib (Stivarga, BAY73-4506); Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 5
States / cities: New Haven, Connecticut • Detroit, Michigan • St Louis, Missouri + 2 more

Conditions: Gastric Adenocarcinoma, Esophageal Adenocarcinoma, Metastasis, HER-2 Gene Amplification
Interventions: Oxaliplatin, Leucovorin, 5 fluorouracil, Trastuzumab, Avelumab; Drug
Lead sponsor: Ashwin Somasundaram; Other
Eligibility: 18 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 7
States / cities: Duarte, California • Atlanta, Georgia • Chicago, Illinois + 4 more

Conditions: Lapsed Contact Lens Wear
Interventions: senofilcon A, senofilcon A for Astigmatism; Device
Lead sponsor: Johnson & Johnson Vision Care, Inc.; Industry
Eligibility: 18 Years to 40 Years
Enrollment: 199 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2014
U.S. locations: 10
States / cities: Jacksonville, Florida • Saint Augustine, Florida • Sarasota, Florida + 7 more

Conditions: Cataract Senile
Interventions: Cataract Surgery; Device
Lead sponsor: Carl Zeiss Meditec, Inc.; Industry
Eligibility: 22 Years to 100 Years
Enrollment: 284 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 14
States / cities: Beverly Hills, California • Northridge, California • Orange, California + 11 more

Conditions: Depressive Disorder, Anxiety
Interventions: JNJ-42165279, Placebo; Drug · Other
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years to 64 Years
Enrollment: 161 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 8
States / cities: Costa Mesa, California • Oceanside, California • Miami, Florida + 5 more

Conditions: Amyotrophic Lateral Sclerosis
Interventions: MN-166, placebo; Drug
Lead sponsor: MediciNova; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 234 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2028
U.S. locations: 10
States / cities: Orange, California • Jacksonville, Florida • Augusta, Georgia + 7 more

Conditions: Knee Osteoarthritis
Interventions: Durolane, PBS; Device
Lead sponsor: Galderma R&D; Industry
Eligibility: 40 Years to 80 Years
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 25
States / cities: Anniston, Alabama • Mobile, Alabama • Phoenix, Arizona + 22 more

Conditions: Hepatic Impairment, Healthy Volunteers
Interventions: BMS-986369; Drug
Lead sponsor: Celgene; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 29 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 3
States / cities: Chandler, Arizona • Orlando, Florida • San Antonio, Texas

Conditions: Allergic Conjunctivitis
Interventions: CsA high dose, CsA low dose, PA, Placebo; Drug
Lead sponsor: Fovea Pharmaceuticals SA; Industry
Eligibility: 18 Years and older
Enrollment: 716 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010
U.S. locations: 1
States / cities: Andover, Massachusetts

Conditions: Chronic Spontaneous Urticaria (CSU)
Interventions: Remibrutinib, Remibrutinib matching placebo, Dupilumab, Placebo solution for injection; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 409 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 121
States / cities: Birmingham, Alabama • Litchfield Park, Arizona • Payson, Arizona + 98 more

Conditions: ADHD, ADD
Interventions: Dexmethylphenidate HCl extended-release capsules; Drug
Lead sponsor: Novartis; Industry
Eligibility: 6 Years to 12 Years
Enrollment: 252 participants
Timeline: 2006
U.S. locations: 25
States / cities: Mesa, Arizona • Little Rock, Arkansas • Los Angeles, California + 21 more

Conditions: Parkinson Disease
Interventions: LY4006896, Placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 30 Years to 85 Years
Enrollment: 90 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2028
U.S. locations: 11
States / cities: Los Alamitos, California • Maitland, Florida • Naples, Florida + 7 more

Search by objective public record fields.

Study of the Efficacy and Safety of AMAG-423 (Digoxin Immune Fab) in Antepartum Subjects With Severe Preeclampsia

A Clinical Trial for the Surgical Treatment of Elderly Distal Radius Fractures

Study of Recombinant Factor VIII Fc Fusion Protein (rFVIIIFc) in Subjects With Severe Hemophilia A

CIS001 Extension Study of Cyclosporine Inhalation Solution

Safety and Efficacy of Obatoclax Mesylate (GX15-070MS) in the Treatment of Hodgkin's Lymphoma

A Study of Multiple Doses of Nusinersen (ISIS 396443) Delivered to Infants With Genetically Diagnosed and Presymptomatic Spinal Muscular Atrophy

7-week Study With CT-155 in People With Schizophrenia

Study of Vorinostat With Doxil and Bortezomib for Patients With Relapsed/Refractory Multiple Myeloma

A Phase 3 Study of SYM-1219 Treatment of Women and Post-Menarchal Adolescent Girls With Bacterial Vaginosis

A Study to Evaluate the Safety and Tolerability of ABBV-0805 in Patients With Parkinson's Disease

An Open-label Study of Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) in Combination With ARPI Versus AAA617 in PSMA Positive First-line mCRPC

A Trial Investigating the Efficacy and Safety of Insulin Detemir Versus Insulin NPH in Combination With Metformin and Diet/Exercise in Children and Adolescents With Type 2 Diabetes Insufficiently Controlled on Metformin With or Without Other Oral Antidiabetic Drug(s) With or Without Basal Insulin

Refametinib (BAY86-9766) in Combination With Regorafenib (Stivarga, BAY73-4506) in Patients With Advanced or Metastatic Cancer

Trial of mFOLFOX6 + Trastuzumab + Avelumab in Gastric and Esophageal Adenocarcinomas

Clinical Evaluation of Lapsed Contact Lens Wearers Who Are Re-fit Into Senofilcon A Contact Lenses

AT ELANA 841P Posterior Chamber Intraocular Lens for Correction of Aphakia Following Cataract Removal

An Efficacy, Safety and Tolerability Study of JNJ-42165279 in Participants With Major Depressive Disorder With Anxious Distress

Evaluation of MN-166 (Ibudilast) for 12 Months Followed by an Open-label Extension for 6 Months in Patients With ALS

Durolane Versus Phosphate Buffered Saline (PBS) in Knee Osteoarthritis

Study to Assess Drug Levels and Safety of Golcadomide (BMS-986369) in Healthy Participants and Participants With Different Degrees of Hepatic Impairment

Study Evaluating the Efficacy of Administration of Cyclosporine (Low Dose and High Dose) and Prednisolone Acetate Compared to Its Components and Vehicle in Patients With Allergic Conjunctivitis

A Study to Evaluate Efficacy of Remibrutinib Compared to Dupilumab at Early Timepoints in Adults With Chronic Spontaneous Urticaria Inadequately Controlled by Second Generation H1-antihistamines

Efficacy, Tolerability and Safety of Dexmethylphenidate HCl Extended-Release Capsules in Children With Attention-Deficit/Hyperactivity Disorder

A Study of LY4006896 in Healthy Participants and Participants With Parkinson's Disease